Compare Enveric Biosciences Inc (ENVB) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs LTC Properties Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while LTC Properties Inc trades at $42.44 (market cap $2.27B). The key difference: LTC Properties Inc is far larger — about 333.8× Enveric Biosciences Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and LTC Properties Inc for 89 Days on average.
| ENVB | LTC | |
|---|---|---|
Market Cap | $6.80M | $2.27B |
Volume | 64,867 | 574,171 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $43.50 |
52-Week Low | $1.27 | $33.98 |
Typical Hold Time | 14 Days | 89 Days |
Enterprise Value | -$1.49M | $3.01B |
Dividend Yield | — | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
LTC Properties trades at $42.37, up 1.34% with a bullish technical signal. The REIT shows strong fundamentals with 2025 revenue of $262.85M and net income of $117.97M, delivering a 38.93% net margin. Recent acquisitions totaling $360M accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Analyst consensus sits at $49.67 with mixed ratings (7 Buy, 12 Hold, 3 Sell) amid strategic shifts.
Outlook remains positive due to demographic tailwinds in senior housing, though rising rates and execution risks on $730M asset sales pose challenges. Current valuation at P/E 15.02 appears reasonable for growth prospects, with technical support at $41-42 offering near-term stability. The stock presents a balanced opportunity for income and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
